AbbVie secured exclusive global rights to ISB 2001, a trispecific T-cell engager developed by Ichnos Glenmark Innovation targeting BCMA, CD38, and CD3 for relapsed/refractory multiple myeloma. Phase I data presented at ASCO showed promising overall response rates of 79% with 30% complete responses and a favorable safety profile. The trispecific antibody design aims to improve avidity and therapeutic efficacy compared to bispecifics, emphasizing the emerging frontier in multispecific immuno-oncology therapeutics.